AUTL:NSD-Autolus Therapeutics Ltd (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 3.51

Change

-0.22 (-5.90)%

Market Cap

USD 0.93B

Volume

4.63M

Analyst Target

USD 26.33
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-11 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

-11.72 (-2.34%)

USD 121.60B
REGN Regeneron Pharmaceuticals Inc

-4.68 (-0.57%)

USD 92.70B
ALNY Alnylam Pharmaceuticals Inc

-10.87 (-3.88%)

USD 36.09B
ARGX argenx NV ADR

+5.01 (+0.85%)

USD 35.78B
BGNE BeiGene Ltd

-11.40 (-5.56%)

USD 22.85B
MRNA Moderna Inc

+0.72 (+1.68%)

USD 21.00B
UTHR United Therapeutics Corporatio..

+0.43 (+0.11%)

USD 16.70B
RPRX Royalty Pharma Plc

-0.36 (-1.37%)

USD 16.11B
INCY Incyte Corporation

-0.95 (-1.17%)

USD 14.67B
SMMT Summit Therapeutics PLC

-1.01 (-4.64%)

USD 13.75B

ETFs Containing AUTL

HOML 8.77 % 0.00 %

N/A

N/A
CLAW 6.09 % 0.95 %

N/A

N/A
ITB 4.30 % 0.42 %

N/A

N/A
PEZ Invesco DWA Consumer Cycl.. 4.09 % 0.60 %

-1.96 (-1.08%)

USD 0.07B
FOVL iShares Focused Value Fac.. 3.96 % 0.25 %

-0.58 (-1.08%)

USD 0.03B
RFG Invesco S&P MidCap 400® .. 2.15 % 0.35 %

-0.62 (-1.08%)

N/A
HOMZ The Hoya Capital Housing .. 1.60 % 0.00 %

-0.93 (-1.08%)

USD 0.05B
CNCR Loncar Cancer Immunothera.. 1.51 % 0.79 %

-0.65 (-1.08%)

USD 0.01B
AFMC First Trust Active Factor.. 1.47 % 0.00 %

-0.37 (-1.08%)

USD 0.01B
ZEUS:CA 1.40 % 0.73 %

N/A

N/A
EZM WisdomTree U.S. MidCap Ea.. 1.15 % 0.38 %

-0.62 (-1.08%)

N/A
WDSC:LSE SPDR MSCI World Small Cap.. 0.20 % 0.00 %

-1.28 (-1.08%)

N/A
WOSC:LSE SPDR MSCI World Small Cap.. 0.20 % 0.00 %

-0.35 (-1.08%)

N/A
WLDS:LSE iShares MSCI World Small .. 0.19 % 0.00 %

-0.03 (-1.08%)

N/A
WSML:LSE iShares MSCI World Small .. 0.19 % 0.00 %

-0.09 (-1.08%)

N/A
IUSN:F iShares MSCI World Small .. 0.19 % 0.00 %

-0.08 (-1.08%)

N/A
ONEO SPDR® Russell 1000 Momen.. 0.00 % 0.20 %

-0.87 (-1.08%)

N/A
VAMO 0.00 % 0.64 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -45.50% 30% F 18% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -45.50% 30% F 18% F
Trailing 12 Months  
Capital Gain -4.10% 46% F 33% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -4.10% 46% F 32% F
Trailing 5 Years  
Capital Gain -68.46% 47% F 20% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -68.46% 47% F 19% F
Average Annual (5 Year Horizon)  
Capital Gain 0.46% 47% F 40% F
Dividend Return 0.46% 47% F 36% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 79.62% 45% F 26% F
Risk Adjusted Return 0.58% 47% F 35% F
Market Capitalization 0.93B 80% B- 70% C-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector